116 related articles for article (PubMed ID: 32552000)
1. Identification of
Zhang M; Wang HZ; Li HO; Zhou YJ; Peng RY; Liu J; Zhao Q
DNA Cell Biol; 2020 Sep; 39(9):1639-1648. PubMed ID: 32552000
[TBL] [Abstract][Full Text] [Related]
2. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
Dai D; Shi R; Han S; Jin H; Wang X
Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
[TBL] [Abstract][Full Text] [Related]
3. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
4. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
Dodin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
[TBL] [Abstract][Full Text] [Related]
5. Differential expression analysis of genes and long non-coding RNAs associated with KRAS mutation in colorectal cancer cells.
Saliani M; Jalal R; Javadmanesh A
Sci Rep; 2022 May; 12(1):7965. PubMed ID: 35562390
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.
Eilertsen IA; Sveen A; Strømme JM; Skotheim RI; Nesbakken A; Lothe RA
Int J Cancer; 2019 Feb; 144(4):841-847. PubMed ID: 30121958
[TBL] [Abstract][Full Text] [Related]
7. COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS.
Zhang Z; Fang C; Wang Y; Zhang J; Yu J; Zhang Y; Wang X; Zhong J
Int J Oncol; 2018 Nov; 53(5):1869-1880. PubMed ID: 30132520
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.
Wen Q; Dunne PD; O'Reilly PG; Li G; Bjourson AJ; McArt DG; Hamilton PW; Zhang SD
Oncotarget; 2017 Jan; 8(2):3206-3225. PubMed ID: 27965461
[TBL] [Abstract][Full Text] [Related]
9. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H; Eshima K
Eur J Cancer; 2011 Sep; 47(13):1946-54. PubMed ID: 21531130
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
11. Identification of key pathways and genes in mutant KRAS colorectal cancer by integrated bioinformatics analysis.
Zhang H; Zhang X; Chen X; Zhang W; Xian J; Zhou X; Yang J; Wang J
Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):615-617. PubMed ID: 29688256
[No Abstract] [Full Text] [Related]
12. GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
Xu K; Wang J; Gao J; Di J; Jiang B; Chen L; Wang Z; Wang A; Wu F; Wu W; Shen L; Su X
Oncol Rep; 2016 Sep; 36(3):1672-8. PubMed ID: 27460045
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
14. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.
Vakil L; Najafipour R; Rakhshani N; Zamani F; Morakabati A; Javadi A
Tumour Biol; 2016 Jul; 37(7):8841-8. PubMed ID: 26749281
[TBL] [Abstract][Full Text] [Related]
15. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients.
Liu J; Huang X; Liu H; Wei C; Ru H; Qin H; Lai H; Meng Y; Wu G; Xie W; Mo X; Johnson CH; Zhang Y; Tang W
J Transl Med; 2021 Jan; 19(1):27. PubMed ID: 33413474
[TBL] [Abstract][Full Text] [Related]
16. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
17. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
[TBL] [Abstract][Full Text] [Related]
18. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.
Chu PC; Lin PC; Wu HY; Lin KT; Wu C; Bekaii-Saab T; Lin YJ; Lee CT; Lee JC; Chen CS
Oncogene; 2018 Jun; 37(25):3440-3455. PubMed ID: 29559746
[TBL] [Abstract][Full Text] [Related]
19. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value.
Xie MZ; Li JL; Cai ZM; Li KZ; Hu BL
BMC Gastroenterol; 2019 Mar; 19(1):46. PubMed ID: 30917791
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
